Study characteristics of included studies.

IntroductionDyslipidemia is a common public health problem in people living with human immunodeficiency virus (HIV) who are receiving antiretroviral therapy and increases the risk of cardiovascular disease. Although evidence indicates that the prevalence of dyslipidemia is high, estimated pooled data are not well documented. Therefore, we aimed to estimate the pooled prevalence of dyslipidemia in adult people living with HIV receiving antiretroviral therapy in Ethiopia.MethodWe conducted a systematic review and meta-analysis of the literature. The following databases and grey literature were searched: PubMed, WorldCat, ScienceDirect, DOAG, African Journals Online, Google Scholar, and African Index Medicine. We included all comparative epidemiological studies that reported the prevalence of high concentration of total cholesterol, triglycerides, and low density lipoprotein, and low concentration of high density lipoprotein cholesterol that were published between January 2003 and July 2023. The random effects model was used to pool the outcome of interest. Additionally, subgrouping, sensitivity analyses, and funnel plots were performed. R software Version 4.2.1 was used for statistical analysis.ResultSeventeen studies with a total of 3929 participants were included in the meta-analysis. The pooled prevalence of dyslipidemia, high total cholesterol, high triglyceride, elevated level of low density lipoprotein and low level of high density lipoprotein cholesterol were 69.32% (95% CI: 63.33, 74.72), 39.78% (95%CI: 32.12, 47.96), 40.32% (95%CI: 34.56, 46.36), 28.58% (95%CI: 21.81, 36.46), and 36.17% (95%CI: 28.82, 44.24), respectively. Age and body mass index were associated with high total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels.ConclusionThe authors concluded that the prevalence of dyslipidemia in Ethiopia is high in people living with HIV receiving antiretroviral therapy. Early detection of dyslipidemia and its integration into treatment are essential for preventing cardiovascular disease.Trial registrationProtocol registered with PROSPERO (CRD42023440125).引言 血脂异常（dyslipidemia）是接受抗反转录病毒治疗的人类免疫缺陷病毒（human immunodeficiency virus, HIV）感染者常见的公共卫生问题，可增加心血管疾病的发病风险。尽管已有证据表明血脂异常的患病率较高，但相关汇总估算数据尚未得到充分记录。因此，本研究旨在估算埃塞俄比亚境内接受抗反转录病毒治疗的成年HIV感染者的血脂异常汇总患病率。方法 本研究开展了系统评价与荟萃分析。检索了以下数据库及灰色文献：PubMed、WorldCat、ScienceDirect、DOAG、非洲在线期刊（African Journals Online）、Google Scholar以及非洲索引医学（African Index Medicine）。纳入2003年1月至2023年7月期间发表的、报告了总胆固醇、甘油三酯、低密度脂蛋白浓度升高以及高密度脂蛋白胆固醇浓度降低相关血脂异常患病率的所有对比性流行病学研究。采用随机效应模型合并目标结局指标，此外还进行了亚组分析、敏感性分析及漏斗图分析。统计分析使用R软件4.2.1版本完成。结果 本荟萃分析共纳入17项研究，总计3929名受试者。血脂异常、高总胆固醇血症、高甘油三酯血症、低密度脂蛋白水平升高以及高密度脂蛋白胆固醇水平降低的汇总患病率分别为69.32%（95%CI：63.33, 74.72）、39.78%（95%CI：32.12, 47.96）、40.32%（95%CI：34.56, 46.36）、28.58%（95%CI：21.81, 36.46）及36.17%（95%CI：28.82, 44.24）。年龄与体质量指数与总胆固醇、甘油三酯及低密度脂蛋白胆固醇水平升高存在相关性。结论 本研究结论显示，埃塞俄比亚接受抗反转录病毒治疗的HIV感染者中血脂异常患病率较高。及早检出血脂异常并将其整合至治疗体系中，对预防心血管疾病具有重要意义。试验注册 本研究方案已在PROSPERO平台注册（CRD42023440125）。